製品番号: HY-125269

TED-347

11 Cited Publications

カスタマーレビュー

Based on 11 publication(s) in Google Scholar

TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC₅₀ of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a K_i of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.13%
CAS 番号: 2378626-29-8
分子式: C₁₅H₁₁ClF₃NO
分子量:313.70

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

TED-347 構造式

CAS 番号: 2378626-29-8

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

IC₅₀ & Target

YAP/TAZ-TEAD

YAP アイソフォーム固有の製品をすべて表示 :

体外実験

TED-347 (0.5-100 μM; 48 hours) inhibits GBM43 cancer cell viability^[1].
TED-347 (5 μM; 48 hours) inhibits co-immunoprecipitation of Myc-tagged TEAD4 with FLAG-tagged Yap1^[1].
TED-347 (10 μM; 48 hours) shows a significant reduction in CTGF transcript levels^[1].
TED-347 (0.5-100 μM; 24 hours) reduces reporter activity in cells transfected with a TEAD reporter. TED-347 (0.5-100 μM) also inhibits TEAD4 transcriptional activity in GBM43 cells^[1].
TED-347 is selective for TEADs and inhibits TEAD2 with the same efficacy. TED-347 (0.1-100 μM; 24-48 hours) inhibits TEAD4 binding to full-length Yap1 in dose- and time-dependent manner. TED-347 (1-100 μM) shows no inhibition of uPAR uPA or Cav2.2 α β protein-protein interactions. Non-covalent binding of TED-347 to TEAD4 exhibits little change to the TEAD4 Yap1 binding affinity^[1].
TED-347 has the maximum rate of inactivation of 0.038 hours, corresponding to a t_1/2^∞ of 18.2 hours^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

GBM43 glioblastoma cell lines
Concentration:

0.5, 1, 10, 100 μM
Incubation Time:

48 hours
Result:

Inhibited GBM43 cancer cell viability and inhibited GBM43 cell viability by 30% at 10 μM.

Western Blot Analysis^[1]

Cell Line:

HEK-293 cells
Concentration:

5 μM
Incubation Time:

48 hours
Result:

Showed a significant loss of co-immunoprecipitation of Myc-tagged TEAD4 with FLAG-tagged Yap1.

RT-PCR^[1]

Cell Line:

HEK-293 cells
Concentration:

10 μM
Incubation Time:

48 hours
Result:

Showed a significant reduction in CTGF transcript levels versus control cells and had no inhibition on TEAD mutant transcriptional activity and protein-protein interactions in cell culture.

化学情報

CAS 番号 2378626-29-8
性状 Solid
分子量 313.70
分子式 C₁₅H₁₁ClF₃NO
Color Light yellow to green yellow
SMILES

O=C(C1=CC=CC=C1NC2=CC=CC(C(F)(F)F)=C2)CCl
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All RT-PCRCell Migration/Invasion AssayIn Vivo Efficacy StudyWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. [Abstract]

2024 Mar 9;9(1):65. PMID: 38461173
Nat Commun

GPRC5A promotes lung colonization of esophageal squamous cell carcinoma. [Abstract]

2024 Nov 16;15(1):9950. PMID: 39550386

TED-347 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 16;15(1):9950. [Abstract]

Transwell migration, invasion, foci formation assays of YAP1 downstream genes following knockdown via shRNAs targeting YAP1 or treatment with two pharmacological YAP-TEAD inhibitors (CA3 and TED-347) in GPRC5A-overexpressing KYSE30 cells.

TED-347 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 16;15(1):9950. [Abstract]

Immunoblotting of YAP1 downstream genes following knockdown via shRNAs targeting YAP1 or treatment with two pharmacological YAP-TEAD inhibitors (CA3 and TED-347) in GPRC5A-overexpressing KYSE30 cells.
J Exp Clin Cancer Res

Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. [Abstract]

2021 Mar 1;40(1):88. PMID: 33648545

TED-347 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. [Abstract]

RT-PCR analysis was used to detect the mRNA expression levels of CTGF and CYR61 in pancreatic cancer cells infected with sh-Control or sh-WDR3 #1 and treated with or without TED-347 (10 μM).

TED-347 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. [Abstract]

PANC-1 cells infected with sh-Control or sh-WDR3 #1 were subcutaneously injected into nude mice. The mice were treated with TED-347 3 times on days 1, 4, and 7 at a dose of 20 mg/kg. The tumor volume was decreased.

TED-347 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. [Abstract]

PANC-1 cells infected with sh-Control or sh-WDR3 #1 and treated with or without TED-347 (10 μM) were harvested for MTS.
Prog Orthod

KAT6A/YAP/TEAD4 pathway modulates osteoclastogenesis by regulating the RANKL/OPG ratio on the compression side during orthodontic tooth movement. [Abstract]

2024 Aug 12;25(1):29. PMID: 39129034
Biochim Biophys Acta Mol Cell Res

Development of a TEAD-independent reporter system for specific and sensitive measurement of YAP/TAZ activity. [Abstract]

2026 Mar;1873(3):120111. PMID: 41534572
Exp Dermatol

Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers. [Abstract]

2022 Oct;31(10):1477-1499. PMID: 35913427
FEBS Lett

Pan-cancer multi-omics analyses reveal crosstalk between the Hippo and immune signaling pathways in the tumor microenvironment. [Abstract]

2022 Feb;596(4):449-464. PMID: 34855209
PLoS One

Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma. [Abstract]

2024 Jul 31;19(7):e0305121. PMID: 39083549
Res Sq

2025 May 15.
bioRxiv

2025 April 14.
bioRxiv

2024 November 17.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (318.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1878 mL

15.9388 mL

31.8776 mL

5 mM

0.6376 mL

3.1878 mL

6.3755 mL

10 mM

0.3188 mL

1.5939 mL

3.1878 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 6.25 mg/mL (19.92 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (7.97 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (554 KB)
- English - EN (554 KB)
- Français - FR (554 KB)
- Deutsch - DE (554 KB)
- Norwegian - NO (554 KB)
- Español - ES (554 KB)
- Swedish - SV (554 KB)
- Italian - IT (554 KB)
- Korean - KR (554 KB)
- Portuguese - PT (554 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Khuchtumur Bum-Erdene, et al. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction. Cell Chem Biol. 2019 Mar 21;26(3):378-389.e13. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1878 mL	15.9388 mL	31.8776 mL	79.6940 mL
	5 mM	0.6376 mL	3.1878 mL	6.3755 mL	15.9388 mL
	10 mM	0.3188 mL	1.5939 mL	3.1878 mL	7.9694 mL
	15 mM	0.2125 mL	1.0626 mL	2.1252 mL	5.3129 mL
	20 mM	0.1594 mL	0.7969 mL	1.5939 mL	3.9847 mL
	25 mM	0.1275 mL	0.6376 mL	1.2751 mL	3.1878 mL
	30 mM	0.1063 mL	0.5313 mL	1.0626 mL	2.6565 mL
	40 mM	0.0797 mL	0.3985 mL	0.7969 mL	1.9923 mL
	50 mM	0.0638 mL	0.3188 mL	0.6376 mL	1.5939 mL
	60 mM	0.0531 mL	0.2656 mL	0.5313 mL	1.3282 mL
	80 mM	0.0398 mL	0.1992 mL	0.3985 mL	0.9962 mL
	100 mM	0.0319 mL	0.1594 mL	0.3188 mL	0.7969 mL

TED-347

11 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

TED-347

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 TED-347

YAP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (11)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

TED-347

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 TED-347

YAP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (11)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

TED-347 関連分類

HY-125269 関連分類